Last edition
News about Global Pharma
Avixgen, US Biotech Firm Ink USD 360 Mn Deal for Next-Gen Drug Delivery Platform
Avixgen has signed a licensing-out agreement worth approximately USD 360 million with a US biotechnology company for its next-generation drug delivery platform, ACP (Advanced Cell Penetrating Peptide).
Global Pharma | 19/08/2025 | By Dineshwori | 324
Skyhawk Therapeutics has entered a strategic research collaboration worth over USD 2 billion with Merck KGaA, Darmstadt, Germany to develop novel RNA-targeting small molecules for neurological disorders.
Global Pharma | 19/08/2025 | By Mrinmoy Dey | 264
Glenmark Pharmaceuticals to Launch Micafungin for Injection in US in September 2025
Glenmark Pharmaceuticals Inc., USA has announced the September 2025 launch of Micafungin for Injection USP, 50 mg and 100 mg vials, the bioequivalent of Astellas Pharma’s Mycamine.
Global Pharma | 19/08/2025 | By Mrinmoy Dey | 282
Remegen Partners with Santen To Commercialise RC28-E in Greater China and Asian Countries
RemeGen, a leading Chinese biopharmaceutical company, has entered into an exclusive licensing agreement for the ophthalmic innovative drug RC28-E with Santen China, a wholly-owned subsidiary of Santen Pharmaceutical.
Global Pharma | 19/08/2025 | By Dineshwori | 413
Atezolizumab will be provided by Genentech for use in Pilatus’ clinical research; PLT012 is Pilatus’ immunomodulatory candidate.
Global Pharma | 18/08/2025 | By Abha | 228
Marksans Pharma's UK Subsidiary Relonchem Secures Multiple MHRA Approvals
Marksans Pharma's wholly owned UK subsidiary, Relonchem Ltd., has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for Metformin Hydrochloride Relonchem Prolonged Release Tablets in three strengths—500 mg, 750 mg, and 1000 mg.
Global Pharma | 18/08/2025 | By Dineshwori | 515
Kwality Pharma Receives Registration for Anti-Cancer Drug Bleomycin 15 IU In Mexico
Kwality Pharmaceuticals has received product registration for Bleomycin 15 IU in Mexico for sale and distribution, expanding its oncology portfolio in regulated markets
Global Pharma | 18/08/2025 | By Dineshwori | 210
UK Approves Sanofi's Teplizumab to Delay Onset of Stage 3 Type 1 Diabetes
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teplizumab (Tzield) to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D.
Global Pharma | 18/08/2025 | By Dineshwori | 257
Tonix Pharmaceuticals Secures FDA Nod for Tonmya, a First-in-Class Therapy for Fibromyalgia
Tonix Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Tonmya (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults.
Global Pharma | 18/08/2025 | By Dineshwori | 383
Alembic Secures Final USFDA Nod for Tretinoin Cream USP, 0.025%
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Tretinoin Cream USP, 0.025 percent, indicated for the treatment of acne vulgaris.
Global Pharma | 16/08/2025 | By Dineshwori | 625
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy